Printer Friendly

OptiBiotix licenses LPLDL to Italian pharma company.

M2 EQUITYBITES-June 21, 2018-OptiBiotix licenses LPLDL to Italian pharma company


OptiBiotix Health plc (AIM: OPTI) has entered into an exclusive licence agreement with Italy's Alfasigma SpA, the life sciences company announced on Thursday.

Under the 10-year agreement, Alfasigma will exclusively commercialise food supplements containing OptiBiotix's cholesterol and blood pressure reducing LPLDL strain in Italy.

OptiBiotix will receive an undisclosed upfront payment and royalties with five figure guaranteed annual minimum payments.

Following on from the launch of LPLDL in the United States, the new agreement extends the commercialisation of LPLDL into Italy, the largest probiotic supplements market in Europe and the second largest market in the world.

The value of Italy's probiotic supplements market is estimated by Euromonitor to be at least USD500m, with annual growth of 25% forecast through to 2021.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 21, 2018
Previous Article:SunTrust approved as official bank for Hartsfield-Jackson Atlanta International Airport.
Next Article:Cynata reports positive 28-day results in latest GvHD trial.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters